Core Viewpoint - JBS N.V. shares have increased by 14.4% recently, with analysts suggesting a potential upside of 41.8% based on a mean price target of $21.4 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of 10 short-term price targets, with a standard deviation of $1.85, indicating variability among analysts [2]. - The lowest estimate is $19.50, suggesting a 29.2% increase, while the highest estimate is $26.00, indicating a potential surge of 72.3% [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about JBS's earnings prospects, with a positive trend in earnings estimate revisions [11]. - The Zacks Consensus Estimate for the current year has risen by 1.3% over the past month, with two estimates increasing and no negative revisions [12]. - JBS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they rarely predict actual stock price movements [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Group 1 - Dutch Bros (BROS) shares have increased by 4.5% over the past four weeks, closing at $65.4, with a mean price target of $82.88 indicating a potential upside of 26.7% [1] - The mean estimate consists of 16 short-term price targets with a standard deviation of $6.27, where the lowest estimate is $73.00 (11.6% increase) and the highest is $95.00 (45.3% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 13.6% over the past month [11][12] Group 2 - The Zacks Rank for BROS is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While price targets can be misleading, the direction implied by the consensus price target suggests potential upside for BROS [10][14] - Analysts' price targets may be influenced by business incentives, leading to overly optimistic estimates [8][9]

Core Viewpoint - Enovis (ENOV) has shown a significant price increase of 12.4% over the past four weeks, with a mean price target of $52.4 indicating a potential upside of 77.3% from its current price of $29.55 [1] Price Targets and Analyst Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $11.51, suggesting variability in analyst predictions. The lowest estimate is $33.00 (11.7% increase), while the highest is $75.00 (153.8% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about ENOV's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. This correlation between earnings revisions and stock price movements supports the expectation of potential upside [11] - Over the last 30 days, three earnings estimates for the current year have been revised higher, leading to a 2.9% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - ENOV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] - While the consensus price target may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - Rapt Therapeutics (RAPT) shares have increased by 0.5% over the past four weeks, closing at $11.74, with a mean price target of $23.6 indicating a potential upside of 101% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $12.24, where the lowest estimate is $9.00 (23.3% decline) and the highest is $38.00 (223.7% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 13.2% over the past month [11][12] Group 2 - RAPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The consensus price target may not be a reliable indicator of the stock's potential gain, but it does suggest a positive direction for price movement [14]

Core Viewpoint - West Pharmaceutical Services (WST) has shown a significant price increase of 11.1% over the past four weeks, with a mean price target of $316.82 indicating a potential upside of 28.7% from the current price of $246.2 [1] Price Targets and Analyst Consensus - The average price target for WST is based on 11 short-term estimates, ranging from a low of $260.00 to a high of $355.00, with a standard deviation of $34.23, suggesting variability in analyst predictions [2] - The lowest estimate indicates a 5.6% increase, while the highest suggests a 44.2% upside, highlighting the range of analyst expectations [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about WST's earnings prospects, as evidenced by a trend of higher EPS estimate revisions, which correlates with potential stock price increases [11] - Over the last 30 days, four estimates for the current year have been revised upward, resulting in a 7.6% increase in the Zacks Consensus Estimate [12] - WST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research shows that they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors are advised to treat price targets with skepticism and not rely solely on them for investment decisions [10]

Group 1 - Harrow (HROW) shares have increased by 10.7% in the past four weeks, closing at $40.01, with a mean price target of $61.31 indicating a potential upside of 53.2% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $8.32, where the lowest estimate is $52.20 (30.5% increase) and the highest is $76.00 (90% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 39% over the past month [11][12] Group 2 - HROW holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] - While price targets can be misleading, the direction implied by them may serve as a useful guide for potential price movements [10][14]

Core Viewpoint - Passage Bio, Inc. (PASG) has seen a significant stock price increase of 31.5% over the past four weeks, closing at $7.59, with analysts suggesting a potential upside of 1415.2% based on a mean price target of $115 [1][2]. Price Targets and Analyst Estimates - The mean estimate of $115 is derived from four short-term price targets, with the lowest estimate at $40.00 indicating a 427% increase, while the highest target suggests a surge of 3325.6% to $260.00 [2]. - The standard deviation of $103.76 indicates variability among analysts' estimates, with a smaller standard deviation suggesting greater agreement [2][9]. Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher for PASG, which is a positive indicator for potential stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 8.7% over the past month, with no negative revisions, further supporting the optimistic outlook [12]. Zacks Rank and Investment Potential - PASG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]. - While consensus price targets may not be entirely reliable, the direction they imply appears to be a useful guide for potential price movement [14].

Group 1 - The Beachbody Company, Inc. (BODI) shares have increased by 27.3% in the past four weeks, closing at $5.04, with a mean price target of $10.83 indicating a potential upside of 114.9% [1] - The average price targets range from a low of $4.00 to a high of $15.50, with a standard deviation of $6.05, suggesting variability in analyst estimates [2] - Analysts show a consensus that BODI will report better earnings than previously estimated, which historically correlates with stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for BODI's current year earnings has risen by 49.1% over the past month, indicating positive sentiment among analysts [12] - BODI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Alvotech (ALVO) shares have increased by 2.9% recently, closing at $8.65, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $17.5, representing a 102.3% upside [1][2]. Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $7, where the lowest estimate is $14.00 (61.9% increase) and the highest is $28.00 (223.7% increase) [2]. - A low standard deviation indicates a strong agreement among analysts regarding the price targets, suggesting a more reliable consensus [2][9]. Earnings Estimates and Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 6.3%, with one estimate increasing and no negative revisions [12]. Zacks Rank and Investment Potential - ALVO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]. - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14].

Core Viewpoint - KALA Bio (KALA) has shown a significant price increase of 35.9% over the past four weeks, with analysts projecting a mean price target of $13, indicating a potential upside of 74.7% from the current price of $7.44 [1][11]. Price Targets and Analyst Consensus - The average price target for KALA ranges from a low of $12.00 to a high of $15.00, with a standard deviation of $1.73, suggesting a relatively tight clustering of estimates among analysts [2][9]. - The lowest estimate indicates a potential increase of 61.3%, while the highest suggests a 101.6% upside [2]. - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - There is increasing optimism among analysts regarding KALA's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - Over the last 30 days, one estimate has increased, leading to a 1.7% rise in the Zacks Consensus Estimate for the current year [12]. - KALA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]. Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].